1 / 11

V I T IL IG O

V I T IL IG O. April 26th, 1999 Chemistry 412 Rick Helgemo. What is vitiligo?. Autoimmune disorder Genetic link Affects 1-2% of population Difficult to cure Harmful effects. “ Untreated” Vitiligo. Autoimmune disorder.

keahi
Download Presentation

V I T IL IG O

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. VITILIGO April 26th, 1999 Chemistry 412 Rick Helgemo

  2. What is vitiligo? • Autoimmune disorder • Genetic link • Affects 1-2% of population • Difficult to cure • Harmful effects

  3. “Untreated” Vitiligo

  4. Autoimmune disorder • Melanocytes destroyed *Melanocyte-specific differentiation antigens *Tyrosinase, Dopachrome isomerase (TRP-2), gp100, MART-1 • Immunoglobulin G recognizes TRP-2, causing immune response • Possible link to curing melanoma?

  5. Genetic Links • Two types-Segmental and nonsegmental • Polygenic nature, multifactorial inheritance • Autosomal and not linked to race or sex • Linked to other autoimmune diseases • Weakly heritable

  6. Curing Vitiligo Effects • Long and difficult process, rarely 100% effective on individual • Always involves sunlight or ultraviolet light • Physical and chemical methods • Cosmetics • Depigmentation • Psychological counseling

  7. Chemical Treatment Options for Vitiligo • Corticoids • Psoralens (PUVA) • Phenylalanine • P-aminobenzoic acid (PABA) • Cantharidin, a blister beetle secretion

  8. Physical Treatment Options for Vitiligo • Tattooing (micropigmentation) • Autologous skin grafts • Skin grafting using blisters • Autologous melanocyte transplantation • Combination of Sun and Sunscreen

  9. References: • “Anti-tyrosinase-related protein-2 immune response in vitiligo patients…;” Okamoto T, Irie RF, Fujii S, etal.; The Journal of Investigative Dermatology; Dec 1998; 111:1034-1039. • “Autoantibodies to Tyrosinase-related protein-1 detected in the sera… ;” Kemp EH, Waterman EA, Gawkrodger DJ, et al.; British Journal of Dermatology 1998; 139:798-805. • “A systematic review of autologous transplantation methods in vitiligo;” Njoo MD,Westerhof W, Bos JD, Bossuyt PMM; Archives of Dermatology, Dec 1998 134:1543-1549. • “The genetics of vitiligo in Korean patients;” Kim SM, Chung HS, Hann SK; International Journal of Dermatology 1998; 38:908-910. • “On the association between vitiligo and malignant melanoma;” Lindelof B, Hedblad MA, Sigurgeirsson B; Acta Dermatologica Venereologica; 1998 78:483-484. • “Tyrosinase as an autoantigen in patients with vitiligo;” Baharav E, Merimsky O, Shoenfeld Y, et al.; Clinical Experimental Immunology; 1996 105:84-88. • “Nonsurgical repigmentation therapies in vitiligo;” Njoo MD,Westerhof W, Bos JD, Bossuyt PMM; Archives of Dermatology; Dec 1998 134:1532-1540. • “Spontaneous repigmentation of vitiligo patches distant from the autologous skin…;” Malakar S, Dhar S; Dermatology; 1998 197:274.

  10. More References • “Treatment of vitiligo with oral and topical phenylalanine: 6 years of experience;” Camacho F, Mazuecos J; Archives of Dermatology; Feb 1999 135:216-217. • “UV-dependent melanocyte plasticity-The structure-function relationship;” Iyengar B; Indian Journal of Pathological Microbiology; 1996 39(2):105-109. • “Topical application of a melanotropin analogue to vulgar vitiligo dermo-epidermal minigrafts;” Schwartzmann-Solon AM, Visconti MA, Castrucci AML; Brazilian Journal of Medical and Biological Research; 1998 31:1557-1564. • “Repigmentation of vitiligo lesion after beetle dermatitis;” Parsad D, Saini R, Nagpal R; Dermatology; 1998 197:398.

More Related